(NASDAQ:ALLK), a clinical-stage biotechnology company with a market capitalization of $108 million, announced today that it will halt the development of its drug candidate AK006 after it failed to ...

The anticipated results from AK006’s trial are expected to provide a clear indication of its efficacy and safety profile. Tuerkcan believes that AK006’s unique mechanism, which targets Siglec ...

Allakos (ALLK) announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria. In the CSU cohort, 34 adult patients with moderate-to-severe CSU refractory to ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).

Allakos shares collapsed on Monday after the clinical-stage biotechnology company threw in the towel on its AK006 product candidate and said it would slash its workforce by 75%. Shares of Allakos ...

Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme following underwhelming Phase I results. This ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). “While AK006 ...